ABAriel Bensimon

Ariel Bensimon

*This is an algorithmically generated author record based on publicly available information.

Ariel Bensimon has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Solute carrier membrane transporters: emerging targets in CNS disorders

    by Yee Kwan Law, Selene Glück, Enrico Girardi, Ariel Bensimon, S. Andreas Angermayr, Giulio Superti-Furga

    Prominent members of the solute carrier (SLC) superfamily of membrane transporters are established targets of central nervous system (CNS) drugs, including the blockbuster neurotransmitter reuptake inhibitors. Numerous other SLC transporters exhibit dysregulated expression in the CNS relative to other tissues, many of which have been genetically or functionally linked to neurological disorders and may therefore represent tractable therapeutic targets. As key regulators of metabolite and ion fluxes, SLCs shape developmental programmes and cellular states associated with epilepsy, neurodegeneration and autism spectrum disorders. Recent advances in assigning biochemical and cellular functions to previously uncharacterized SLCs, together with emerging chemical strategies to increase or decrease transporter abundance, are expanding the therapeutic landscape and positioning SLC biology at the forefront of next-generation CNS drug discovery.

  • Top Cited Papers

    Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells

    by Fabian Offensperger, Gary Tin, Miquel Duran-Frigola, Elisa Hahn, Sarah Dobner, Christopher W. Am Ende, Joseph W. Strohbach, Andrea Rukavina, Vincenth Brennsteiner, Kevin Ogilvie, et al.

    Chemical modulation of proteins enables a mechanistic understanding of biology and represents the foundation of most therapeutics. However, despite decades of research, 80% of the human proteome lacks functional ligands. Chemical proteomics has advanced fragment-based ligand discovery toward cellular systems, but throughput limitations have stymied the scalable identification of fragment-protein interactions. We report proteome-wide maps of protein-binding propensity for 407 structurally diverse small-molecule fragments. We verified that identified interactions can be advanced to active chemical probes of E3 ubiquitin ligases, transporters, and kinases. Integrating machine learning binary classifiers further enabled interpretable predictions of fragment behavior in cells. The resulting resource of fragment-protein interactions and predictive models will help to elucidate principles of molecular recognition and expedite ligand discovery efforts for hitherto undrugged proteins.


  • Phosphoproteomics reveals novel modes of function and inter‐relationships among PIKKs in response to genotoxic stress

    by Sapir Schlam‐Babayov, Ariel Bensimon, Michal Harel, Tamar Geiger, Ruedi Aebersold, Yael Ziv, Yosef Shiloh

    EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.


  • TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7–9

    by Leonhard X. Heinz, JangEun Lee, Utkarsh Kapoor, Felix Kartnig, Vitaly Sedlyarov, Konstantinos Papakostas, Adrian César-Razquin, Patrick Essletzbichler, Ulrich Goldmann, Adrijana Stefanovic, et al.

    Toll-like receptors (TLRs) have a crucial role in the recognition of pathogens and initiation of immune responses1,2,3. Here we show that a previously uncharacterized protein encoded by CXorf21—a gene that is associated with systemic lupus erythematosus4,5—interacts with the endolysosomal transporter SLC15A4, an essential but poorly understood component of the endolysosomal TLR machinery also linked to autoimmune disease4,6,7,8,9. Loss of this type-I-interferon-inducible protein, which we refer to as ‘TLR adaptor interacting with SLC15A4 on the lysosome’ (TASL), abrogated responses to endolysosomal TLR agonists in both primary and transformed human immune cells. Deletion of SLC15A4 or TASL specifically impaired the activation of the IRF pathway without affecting NF-κB and MAPK signalling, which indicates that ligand recognition and TLR engagement in the endolysosome occurred normally. Extensive mutagenesis of TASL demonstrated that its localization and function relies on the interaction with SLC15A4. TASL contains a conserved pLxIS motif (in which p denotes a hydrophilic residue and x denotes any residue) that mediates the recruitment and activation of IRF5. This finding shows that TASL is an innate immune adaptor for TLR7, TLR8 and TLR9 signalling, revealing a clear mechanistic analogy with the IRF3 adaptors STING, MAVS and TRIF10,11. The identification of TASL as the component that links endolysosomal TLRs to the IRF5 transcription factor via SLC15A4 provides a mechanistic explanation for the involvement of these proteins in systemic lupus erythematosus12,13,14.


  • Open Access

    Deciphering MET‐dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics

    by Ariel Bensimon, Jonas P. Koch, Paola Francica, Selina M. Roth, Rahel Riedo, Astrid A. Glück, Eleonora Orlando, Andree Blaukat, Daniel M. Aebersold, Yitzhak Zimmer, et al.

    Increasing evidence suggests that interference with growth factor receptor tyrosine kinases (RTKs) signaling can affect DNA damage response (DDR) networks, with a consequent impact on cellular responses to DNA‐damaging agents widely used in cancer treatment. In that respect, the MET RTK is deregulated in abundance and/or activity in a variety of human tumors. Using two proteomic techniques, we explored how disrupting MET signaling modulates global cellular phosphorylation response to ionizing radiation (IR). Following an immunoaffinity‐based phosphoproteomic discovery survey we selected candidate phosphorylation sites for extensive characterization by targeted proteomics focusing on phosphorylation sites in both signaling networks. Several substrates of the DDR were confirmed to be modulated by sequential MET inhibition and IR, or MET inhibition alone. Upon combined treatment, for two substrates, NUMA1 S395 and CHEK1 S345, the gain and loss of phosphorylation, respectively, were recapitulated using in vivo tumor models by immunohistochemistry, with possible utility in future translational research. Overall, we have corroborated phosphorylation sites at the intersection between MET and the DDR signaling networks, and suggest that these represent a class of proteins at the interface between oncogene‐driven proliferation and genomic stability.